{"id":532190,"date":"2026-07-04T04:16:53","date_gmt":"2026-07-04T04:16:53","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/532190\/"},"modified":"2026-07-04T04:16:53","modified_gmt":"2026-07-04T04:16:53","slug":"new-biweekly-glp-1-shot-lowers-blood-sugar-supports-weight-loss","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/532190\/","title":{"rendered":"New Biweekly GLP-1 Shot Lowers Blood Sugar, Supports Weight Loss"},"content":{"rendered":"<p><img decoding=\"async\" loading=\"eager\" src=\"https:\/\/www.newsbeep.com\/ie\/wp-content\/uploads\/2026\/07\/Maslows-hierarchy-GettyImages-1999994846-Header.jpg\" alt=\"Close-up of a GLP-1 injection pen\" class=\"css-bt1qz0\"\/><a class=\"icon-hl-pinterest css-foz1gx\" target=\"_blank\" rel=\"noopener noreferrer nofollow\" data-event=\"Any Page|Image Pinterest Click|Icon Clicked\" data-element-event=\"OPEN|CONTENTBLOCK|Any Page|Article Body|BUTTON|Image Widget Pinterest Click|\" href=\"https:\/\/www.pinterest.com\/pin\/create\/button\/?url=https%3A%2F%2Fwww.healthline.com%2Fhealth-news%2Fbiweekly-glp-1-shot-improves-blood-sugar-weight-loss-clinical-trial&amp;media=https%3A%2F%2Fmedia.post.rvohealth.io%2Fwp-content%2Fuploads%2F2026%2F07%2FMaslows-hierarchy-GettyImages-1999994846-Header.jpg&amp;description=New%20Biweekly%20GLP-1%20Shot%20Lowers%20Blood%20Sugar%2C%20Supports%20Weight%20Loss\" title=\"Share on Pinterest\" data-pin-custom=\"true\" data-share-url=\"https:\/\/www.newsbeep.com\/ie\/wp-content\/uploads\/2026\/07\/Maslows-hierarchy-GettyImages-1999994846-Header.jpg\">Share on Pinterest<\/a>A new biweekly GLP-1 injection has been shown to significantly reduce blood sugar in a clinical trial. Image Credit: Hannes P Albert\/picture alliance via Getty ImagesA new GLP-1 medication demonstrated efficacy in reducing blood sugar in people with type 2 diabetes in a phase 2b clinical trial. Bofanglutide is a biweekly (once every 2 weeks) injection compared to once-weekly shots like Ozempic and Wegovy. The new biweekly GLP-1 also led to weight loss and improvement in cardiometabolic risk factors. <\/p>\n<p>GLP-1 drugs like Ozempic and Wegovy are groundbreaking treatments for type 2 diabetes and obesity.<\/p>\n<p>As other drug manufacturers join the GLP-1 race, Gan &amp; Lee Pharmaceuticals in Beijing, China, is developing a novel biweekly GLP-1 for weight loss.<\/p>\n<p>In a phase 2b randomized clinical trial, bofanglutide demonstrated a strong efficacy in reducing blood sugar in people with type 2 diabetes. <\/p>\n<p>If approved, a biweekly shot could offer an alternative to once-weekly GLP-1 injections for the needle-averse.<\/p>\n<p>The phase 2b clinical trial of bofanglutide included 272 adults with type 2 diabetes, with an average age of 50.8, from 37 sites across China. The participants were divided into five treatment groups: <\/p>\n<p>bofanglutide 12 mg (biweekly)bofanglutide 18 mg (biweekly)bofanglutide 24mg (biweekly) bofanglutide 24mg (once weekly)semaglutide 1mg (once weekly) <\/p>\n<p>The primary measurement the researchers focused on was <a href=\"https:\/\/www.healthline.com\/health\/diabetes\/a1c-faqs\" class=\"content-link css-kxhged\" rel=\"nofollow noopener\" target=\"_blank\">HbA1c levels<\/a> from the baseline to the 24-week follow-up. <\/p>\n<p>At the end of 24 weeks, all bofanglutide groups showed significant reductions in blood sugar levels. <\/p>\n<p>Participants taking bofanglutide experienced weight loss and improvements in various cardiometabolic risk factors. <\/p>\n<p>In some cases, blood sugar reductions among those taking bofanglutide were slightly greater than those taking semaglutide. <\/p>\n<p>However, the semaglutide group received a relatively low dose, highlighting the need for further study. <\/p>\n<p>\u201cMore real-world comparisons are needed to determine whether this would be more effective than semaglutide,\u201d said <a href=\"https:\/\/www.memorialcare.org\/providers\/mir-b-ali\" target=\"_blank\" rel=\"noopener noreferrer nofollow\" class=\"content-link css-kxhged\">Mir Ali<\/a>, MD, medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA. Ali wasn\u2019t involved in the study. <\/p>\n<p>The trial\u2019s findings also suggest that bofanglutide could help manage diabetes and obesity. <\/p>\n<p>However, <a href=\"https:\/\/www.cadoganclinic.com\/about-us\/our-consultants\/dr-clare-thompson\/\" target=\"_blank\" rel=\"noopener noreferrer nofollow\" class=\"content-link css-kxhged\">Clare Thompson<\/a>, a general practitioner and lead of the weight management service at Cadogan Clinic in the United Kingdom, further noted the study\u2019s limitations. Thompson wasn\u2019t involved in the study. <\/p>\n<p>\u201cThe study is limited by its relatively small size and by population data from a Chinese cohort, where the starting BMI may be much lower than in Western populations,\u201d she told Healthline. <\/p>\n<p>\u201c[It] does not show what happens to patients after stopping these medications or titrating down to a maintenance dose. Twenty-four weeks is quite a short observation period for drawing full and meaningful conclusions,\u201d she said.<\/p>\n<p>All GLP-1 drugs \u2014 semaglutide, bofanglutide, or tirzepatide \u2014 may cause <a href=\"https:\/\/www.healthline.com\/health\/common-glp-1-side-effects\" class=\"content-link css-kxhged\" rel=\"nofollow noopener\" target=\"_blank\">side effects<\/a>. <\/p>\n<p>Around <a href=\"https:\/\/www.bmj.com\/content\/390\/bmj.r1606\" target=\"_blank\" rel=\"noopener noreferrer nofollow\" class=\"content-link css-kxhged\">40% of people<\/a> using a GLP-1 medication experience nausea, vomiting, diarrhea, or constipation. <\/p>\n<p>Gastrointestinal symptoms, such as nausea, are among the <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5397288\/\" target=\"_blank\" rel=\"noopener noreferrer nofollow\" class=\"content-link css-kxhged\">most common<\/a>.<\/p>\n<p>The researchers who conducted the trial found that while these side effects may be more frequent with bofanglutide, they were generally mild. <\/p>\n<p>Other side effects may include a reaction at the injection site. This may include swelling, pain or discomfort, discoloration, or a rash. <\/p>\n<p>If you take a GLP-1 and experience side effects that concern you, speak with your healthcare professional.<\/p>\n","protected":false},"excerpt":{"rendered":"Share on PinterestA new biweekly GLP-1 injection has been shown to significantly reduce blood sugar in a clinical&hellip;\n","protected":false},"author":2,"featured_media":532191,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[103,61,60],"class_list":["post-532190","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-ie","tag-ireland"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/532190","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=532190"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/532190\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/532191"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=532190"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=532190"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=532190"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}